Literature DB >> 24804993

Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance.

Keon-Il Im1, Min-Jung Park, Nayoun Kim, Jung-Yeon Lim, Hyun-Sil Park, Sung-Hee Lee, Young-Sun Nam, Eun-Sol Lee, Jung-Ho Lee, Mi-La Cho, Seok-Goo Cho.   

Abstract

Establishment of mixed chimerism is an ideal approach to induce donor-specific tolerance while expanding its potential in various clinical settings. Despite the developments in partial conditioning regimens, improvements are still needed in reducing toxicity and bone marrow transplantation-related complications. Recently, cell-based therapies, including mesenchymal stem cells (MSCs), have been incorporated in establishing noncytoreductive mixed chimerism protocols; however, its efficacy is only partial and shows reversed immunosuppressive properties. This study demonstrates a novel approach to induce mixed chimerism and tolerance through combinatory cell-based immune modulation (CCIM) of MSCs and regulatory T cells (Tregs). We hypothesize that the interaction between these cells may lead to greater inhibition of host immune responses. Compared with single cell therapy, CCIM induced a higher engraftment rate and robust donor-specific tolerance to skin allografts across full major histocompatibility complex barriers. These regulatory effects were associated with inhibition of natural killer cell cytotoxic activity, CD4(+)IL-17(+) cells, memory B cells, plasma cells, and immunoglobulin production levels along with increased frequencies of CD4(+)Foxp3(+) cells, IL-10-producing mature B cells, and myeloid-derived suppressor cells. Furthermore, CCIM was able to regulate mortality in a graft-versus-host disease model through reciprocal regulation of Treg/Th17. Taken together, we suggest CCIM as a clinically applicable strategy for facilitating the induction of mixed chimerism and permanent tolerance.

Entities:  

Mesh:

Year:  2014        PMID: 24804993      PMCID: PMC4172387          DOI: 10.1089/scd.2013.0617

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  51 in total

Review 1.  Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction?

Authors:  Alain Le Moine; Michel Goldman
Journal:  Am J Transplant       Date:  2003-02       Impact factor: 8.086

2.  B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection.

Authors:  Hooman Noorchashm; Amy J Reed; Susan Y Rostami; Raha Mozaffari; Ghazal Zekavat; Brigitte Koeberlein; Andrew J Caton; Ali Naji
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

3.  Mesenchymal stem cells facilitate mixed hematopoietic chimerism induction and prevent onset of diabetes in nonobese diabetic mice.

Authors:  Sadaki Asari; Shin Itakura; Jeffrey Rawson; Taihei Ito; Ivan Todorov; Indu Nair; Jonathan Shintaku; Chih-Pin Liu; Fouad Kandeel; Yoko S Mullen
Journal:  Pancreas       Date:  2011-08       Impact factor: 3.327

Review 4.  Essential role for B cells in transplantation tolerance.

Authors:  Robert R Redfield; Eduardo Rodriguez; Ronald Parsons; Kumar Vivek; Moiz M Mustafa; Hooman Noorchashm; Ali Naji
Journal:  Curr Opin Immunol       Date:  2011-10       Impact factor: 7.486

5.  Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients.

Authors:  Silviu Itescu; Elizabeth Burke; Katherine Lietz; Ranjit John; Donna Mancini; Robert Michler; Eric Rose; Mehmet Oz; Niloo Edwards
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

6.  Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.

Authors:  Tatyana B Prigozhina; Gregory Elkin; Sofia Khitrin; Shimon Slavin
Journal:  Exp Hematol       Date:  2004-11       Impact factor: 3.084

Review 7.  Do NK-cell receptors and alloreactivity affect solid organ transplantation?

Authors:  Carlos Vilches; Peter Parham
Journal:  Transpl Immunol       Date:  2006-10-10       Impact factor: 1.708

8.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 9.  The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation.

Authors:  Eun-Jung Kim; Nayoun Kim; Seok-Goo Cho
Journal:  Exp Mol Med       Date:  2013-01-10       Impact factor: 8.718

10.  Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice.

Authors:  G Cudkowicz; M Bennett
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications.

Authors:  Nayoun Kim; Seok-Goo Cho
Journal:  Int J Hematol       Date:  2015-12-11       Impact factor: 2.490

2.  Negative impact of bone-marrow-derived mesenchymal stem cells on dextran sulfate sodium-induced colitis.

Authors:  Young-Sun Nam; Nayoun Kim; Keon-Il Im; Jung-Yeon Lim; Eun-Sol Lee; Seok-Goo Cho
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

3.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

Review 4.  New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation.

Authors:  Nayoun Kim; Seok-Goo Cho
Journal:  Int J Stem Cells       Date:  2015-05       Impact factor: 2.500

5.  Adoptive Transfer of Treg Cells Combined with Mesenchymal Stem Cells Facilitates Repopulation of Endogenous Treg Cells in a Murine Acute GVHD Model.

Authors:  Eun-Sol Lee; Jung-Yeon Lim; Keon-Il Im; Nayoun Kim; Young-Sun Nam; Young-Woo Jeon; Seok-Goo Cho
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

6.  Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis.

Authors:  Jung-Yeon Lim; Keon-Il Im; Eun-Sol Lee; Nayoun Kim; Young-Sun Nam; Young-Woo Jeon; Seok-Goo Cho
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

7.  A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection.

Authors:  Ming Shi; Zhenwen Liu; Ying Wang; Rounan Xu; Yanling Sun; Min Zhang; Xi Yu; Hongbo Wang; Lingzhan Meng; Haibin Su; Lei Jin; Fu-Sheng Wang
Journal:  Stem Cells Transl Med       Date:  2017-12       Impact factor: 6.940

8.  Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells.

Authors:  Min-Jung Park; Jin-Ah Baek; Se-Young Kim; Kyung-Ah Jung; Jeong Won Choi; Sung-Hwan Park; Seung-Ki Kwok; Mi-La Cho
Journal:  J Transl Med       Date:  2020-12-14       Impact factor: 5.531

Review 9.  Combining Adoptive Treg Transfer with Bone Marrow Transplantation for Transplantation Tolerance.

Authors:  Nina Pilat; Nicolas Granofszky; Thomas Wekerle
Journal:  Curr Transplant Rep       Date:  2017-11-04

10.  Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models.

Authors:  Li Wang; Haiyan Zhang; Lixun Guan; Shasha Zhao; Zhenyang Gu; Huaping Wei; Zhe Gao; Feiyan Wang; Nan Yang; Lan Luo; Yonghui Li; Lili Wang; Daihong Liu; Chunji Gao
Journal:  Oncotarget       Date:  2016-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.